NVG-291 was granted Fast Track designation by the FDA in October 2023 and Orphan Drug designation by the European Medicines Agency for the treatment of SCI in February 2021. The company plans to hold an FDA End-of-Phase 2 meeting in early 2026 to align on the development pathway for NVG-291, with enrollment of individuals with subacute SCI in the Phase 1b/2a CONNECT SCI Study ongoing and preparation for a Phase 3 clinical trial in chronic SCI.
Cyborg Score Rationale
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury. The company achieved Nasdaq listing and has FDA catalysts ahead, but faces clinical development risks and limited cash runway ($11.4M as of Q3 2025).
Top Insights
Unprecedented Phase 1b/2a efficacy data in chronic SCI showing durable improvements across functional metrics
Fast Track and Orphan Drug designations provide expedited regulatory pathway with less competition
Current market cap of approximately $469-479M CAD suggests significant optionality premium on Phase 2 data
Cash position of $11.4M as of September 2025 requires additional financing; recent $10M private placement demonstrates investor conviction
Named Competitors
Various SCI therapeutic approaches — Diverse neurology/neuroscience programs with indirect SCI focus
Recent Developments
(November 2025) Announced expanded Phase 1b/2a CONNECT SCI Study data in chronic spinal cord injury showing unprecedented durable improvements
(January 2026) Successfully listed on Nasdaq under symbol NGEN following positive clinical data
(February 2026) Scheduled to participate in multiple upcoming investor conferences
(March 2026) CFO Bill Adams announced retirement effective March 15, 2026
Open the full interactive NervGen Pharma Corp report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.